Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...

BMY's Breyanzi tops $1B run rate in 2025, expanding across five cancers with new FDA nod, strengthening its CAR T leadership ...

• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference ...

In patients with relapsed/refractory mantle cell lymphoma (MCL) who were naive to Bruton tyrosine kinase inhibitor (BTKi) therapy, brexucabtagene autoleucel (brexu-cel) was associated with high ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for ...